Truist Securities Reiterates Buy on Viking Therapeutics, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Joon Lee has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a $32 price target.
June 27, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Joon Lee reiterated a Buy rating on Viking Therapeutics and maintained a $32 price target.
The reiteration of a Buy rating and maintenance of a $32 price target by Truist Securities analyst Joon Lee indicates a positive outlook for Viking Therapeutics. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100